Clinique de Flandre

The medical center is at the forefront of research in Metastatic Breast Cancer, particularly focusing on hormone receptor-positive (HR+) and HER2-negative (HER2-) subtypes. The center's innovative approach involves the detection of tumor DNA in the blood, which serves as a critical tool for selecting patients who may benefit from advanced therapeutic combinations.

• Alpelisib-Fulvestrant Combination
• Ribociclib-Fulvestrant Combination
• PIK3CA ctDNA Mutations

By comparing the efficacy of these combinations, the center aims to enhance Progression-Free Survival (PFS) in patients, thereby contributing significantly to personalized cancer treatment strategies.

Specializing in advanced gastric, oesophageal, and gastroesophageal junction cancers, the center is pioneering studies on treatment regimens for HER2-negative cases. The research focuses on evaluating the effectiveness of novel drug combinations in improving patient outcomes in a palliative setting.

• Trifluridine/Tipiracil + Oxaliplatin
• 5-Fluorouracil + Nivolumab
• FOLFOX Regimen

Through these studies, the center seeks to establish superior treatment protocols that enhance Progression-Free Survival (PFS) for patients with locally advanced, recurrent, or metastatic conditions.